Table 4 Patient characteristics between BRAF V600E and BRAF wild-type MA patients
From: Novel clinicopathological and molecular characterization of metanephric adenoma: a study of 28 cases
n | Total | BRAF V600E | BRAF wild-type |
|---|---|---|---|
27 | 22 | 5 | |
Gender | F:M = 9:18 | F:M = 5:17 | F:M = 1:4* |
Age range, year | 12~ 80 | 25~ 73 | 12~ 47** |
Median age, year | 39 | 40 | 29 |
Tumor size, cm | 2~ 7 | 2.5~ 7 | 2~ 5.5* |
Median size, cm | 3.1 | 3.2 | 2.2 |
BCL2, (negative/positive) | 5/22 | 2/20 | 3/2** |
p16, (negative/positive) | 4/23 | 1/21 | 3/2** |
p-MEK, (negative/positive) | 0/27 | 0/22 | 0/5 |
p-ERK, (negative/positive) | 15/12 | 13/9 | 2/3 |
DUSP6, (negative/positive) | 4/23 | 2/20 | 2/3 |